Emerg Infect Dis. 2019 Jun;25(6):1144-1152. doi: 10.3201/eid2506.181620.
Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiV), discovered in 1998-1999 in Malaysia and Singapore (≈40% CFR); and the Bangladesh strain (NiV), discovered in Bangladesh and India in 2001 (≈80% CFR). Recently, NiV in African green monkeys resulted in a more severe and lethal disease than NiV. No NiV vaccines or treatments are licensed for human use. We assessed replication-restricted single-injection recombinant vesicular stomatitis vaccine NiV vaccine vectors expressing the NiV glycoproteins against NiV challenge in African green monkeys. All vaccinated animals survived to the study endpoint without signs of NiV disease; all showed development of NiV F Ig, NiV G IgG, or both, as well as neutralizing antibody titers. These data show protective efficacy against a stringent and relevant NiV model of human infection.
尼帕病毒(NiV)是一种人畜共患病病原体,可导致人类高病死率(CFR)。两种尼帕病毒株引起了疫情爆发:马来西亚株(NiV),于 1998-1999 年在马来西亚和新加坡发现(CFR 约为 40%);孟加拉国株(NiV),于 2001 年在孟加拉国和印度发现(CFR 约为 80%)。最近,在非洲绿猴中发现的尼帕病毒比尼帕病毒更严重和致命。目前没有获得许可用于人类使用的尼帕病毒疫苗或治疗方法。我们评估了复制受限的单次注射重组水疱性口炎疫苗尼帕病毒疫苗载体,该载体表达尼帕病毒糖蛋白,以针对非洲绿猴中的尼帕病毒挑战。所有接种疫苗的动物都存活到研究终点,没有尼帕病毒病的迹象;所有动物都产生了尼帕病毒 F Ig、尼帕病毒 G IgG 或两者兼有的中和抗体滴度。这些数据显示了针对严格和相关的人类感染尼帕病毒模型的保护效力。